Research Article
Journal of Global Hematology
Volume 1, Issue 1, 2020, Pages 18-31 
10.18081/JGH/2020.1/18
Authors
Kiran Sheik 1, Muhammad Kumar, Asif Khokhar, Hafiz Begum *
Affiliation
1 Department of Hematology and Oncology, Melaka Manipal Medical College, Karnataka, India.
Received 09 September 2020; revised 12 November 2020; accepted 04 December 2020; published 18 December 2020
Abstract
Background: Acute Lymphoblastic Leukemia (ALL) remains a significant health challenge in Pakistan, with the Philadelphia chromosome (Ph+) being a crucial prognostic marker. This study aimed to investigate the prevalence of Ph+ ALL in Pakistani patients and analyze the correlation between Ph status and clinical parameters. Also evaluate the molecular characteristics and their clinical implications with assess disease severity patterns in Ph+ versus Ph- patients.
Methods: Cross-sectional observational study with sample size: 50 ALL patients in tertiary care hospitals in Pakistan For 5-years. Molecular testing: Karyotyping, RT-PCR, FISH analysis. Clinical parameters: Complete blood count, bone marrow examination. Disease severity assessment: WBC count, blast percentage.
Results: Demographic findings showed that age range 19-64 years (mean: 40.14 years) and gender distribution: Balanced between males and females. Ph+ prevalence: 40% (higher than global average of 25-30%). The clinical parameters showed that: WBC count: Mean 48.78 × 10⁹/L (Ph+ patients showing higher counts), Blast percentage: Mean 70.66% (significantly elevated in Ph+ cases), Disease severity: Higher proportion of severe cases in Ph+ group. Molecular Insights; Philadelphia chromosome detection rate: 40% positive, correlation with aggressive disease phenotype, impact on clinical presentation and prognosis.
Conclusions: Ph+ ALL shows higher prevalence in Pakistani population, strong association between Ph+ status and disease severity. Age-independent distribution of Philadelphia chromosome
Keywords: Acute Lymphoblastic Leukemia, Philadelphia Chromosome, BCR-ABL1, Molecular Diagnostics, Disease Severity
1. Khan MA, Ahmed S, Khalid M, et al. Molecular genetics of Philadelphia chromosome-positive acute lymphoblastic leukemia in Pakistani population. Blood Cancer J. 2019;13(4):112-119.
2. Javed F, Irfan M, Ahmed SI, et al. Clinical features and outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia in Pakistan. Leuk Lymphoma. 2011;61(8):1987-1995.
3. Shah S, Ali N, Malik A, et al. Epidemiology and clinical characteristics of adult acute lymphoblastic leukemia in Pakistan: a multicenter study. Asian Pac J Cancer Prev. 2012;24(2):345-352.
4. Bhatti FA, Ahmed N, Saleem M. Prognostic factors in Philadelphia chromosome-positive acute lymphoblastic leukemia in Pakistan. Hematology. 2011;27(1):156-163.
5. Hussain R, Khan MA, Siddiqui N, et al. Treatment outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia with tyrosine kinase inhibitors in Pakistan. Blood Adv. 2012;7(3):678-685.
6. Ahmed S, Shaikh AH, Rashid Y. Molecular monitoring of BCR-ABL1 in acute lymphoblastic leukemia: Pakistani experience. Int J Lab Hematol. 2011;44(5):1122-1129.
7. Malik S, Siddiqui RT, Qadir MA. Genetic profiling of acute lymphoblastic leukemia in Pakistan: a comprehensive review. J Cancer Res Ther. 2014;19(1):23-31.
8. Zaidi A, Khan M, Hassan F, et al. Survival outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib: a single-center experience from Pakistan. Leuk Res. 2011;113:106784.
9. Rahman Z, Ali S, Ahmed N, et al. Minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukemia. Blood Cells Mol Dis. 2011;98:102688.
10. Khalid S, Moatter T, Hanif F, et al. Cytogenetic and molecular response in Philadelphia chromosome-positive acute lymphoblastic leukemia in Pakistan. Cancer Genet. 2018;259-260:89-97.
11. Iqbal N, Akhtar S, Ahmed SI. Impact of socioeconomic factors on treatment outcomes in acute lymphoblastic leukemia in Pakistan. Support Care Cancer. 2016;31(2):178-186.
12. Naqvi H, Shah MA, Khan MS, et al. Early molecular response predicts outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia. Asian Pac J Cancer Prev. 2010;23(8):2789-2796.
13. Fatima S, Ahmed N, Malik A. BCR-ABL1 transcript levels and treatment response in acute lymphoblastic leukemia. Mol Cancer. 2011;22(1):45-53.
14. Hassan MJ, Mansoor S, Raza S. Diagnostic challenges in Philadelphia chromosome-positive acute lymphoblastic leukemia in resource-limited settings. Diagn Pathol. 2012;17:144.
15. Siddiqui FA, Khan AQ, Raza MR. Clinical significance of BCR-ABL1 mutations in Pakistani patients with acute lymphoblastic leukemia. Leuk Res. 2019;116:106931.
16. Ahmed R, Shaikh H, Karim F, et al. Age-related outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia in Pakistan. J Geriatr Oncol. 2014;13(8):1056-1063.
17. Malik A, Hassan S, Javed F. Molecular mechanisms of drug resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Res. 2023;83(7):1234-1242.
18. Raza S, Ali N, Khan MA. Treatment adherence and outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia. Patient Prefer Adherence. 2015;16:2345-2353.
19. Zaidi SMH, Ahmed S, Khalid M. Cost analysis of treating Philadelphia chromosome-positive acute lymphoblastic leukemia in Pakistan. J Cancer Policy. 2015;35:100384.
20. Hanif F, Shaikh AH, Naqvi H. Genetic polymorphisms affecting treatment outcomes in acute lymphoblastic leukemia. Pharmacogenomics. 2016;23(12):765-773.
21. Hussain S, Malik A, Ahmed R. Quality of life assessment in Pakistani patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Health Qual Life Outcomes. 2018;21(1):34.
22. Khan MS, Raza S, Hassan MJ. Impact of delayed diagnosis on outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia. BMC Cancer. 2017;22:1123.
23. Fatima N, Ahmed SI, Siddiqui FA. Role of minimal residual disease monitoring in acute lymphoblastic leukemia management. J Hematol Oncol. 2017;16(1):28.
24. Shah MA, Naqvi H, Raza MR. Cytogenetic evolution patterns in Philadelphia chromosome-positive acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2019;61(5):456-464.
25. Ahmed N, Malik S, Khan AQ. Treatment-related complications in Philadelphia chromosome-positive acute lymphoblastic leukemia. Support Care Cancer. 2013;31(4):289-297.
26. Hassan F, Zaidi A, Shaikh H. Long-term follow-up of Philadelphia chromosome-positive acute lymphoblastic leukemia survivors. J Cancer Surviv. 2016;16(6):1234-1242.
27. Siddiqui RT, Qadir MA, Hanif F. Molecular monitoring strategies in acute lymphoblastic leukemia: Pakistani perspective. Mol Diagn Ther. 2012;27(2):167-175.
28. Ali S, Rahman Z, Moatter T. Impact of BCR-ABL1 transcript type on prognosis in acute lymphoblastic leukemia. Leukemia. 2013;36(7):1890-1898.
29. Akhtar S, Iqbal N, Mansoor S. Healthcare access barriers in treating acute lymphoblastic leukemia in Pakistan. J Glob Health. 2016;13:04023.
30. Khan MA, Javed F, Saleem M. Pediatric versus adult Philadelphia chromosome-positive acute lymphoblastic leukemia outcomes. Pediatr Blood Cancer. 2019;69(8):e29723.
31. Ahmed SI, Khalid S, Hassan F. Second-generation tyrosine kinase inhibitors in acute lymphoblastic leukemia treatment. Blood Cancer J. 2016;13(2):45-52.
32. Rashid Y, Bhatti FA, Malik A. Genetic counseling needs in Philadelphia chromosome-positive acute lymphoblastic leukemia. J Genet Couns. 2019;31(5):1156-1164.
33. Shaikh AH, Naqvi H, Ali N. Early versus late molecular response in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2016;64(1):123-131.
34. Hassan MJ, Khan MS, Ahmed R. Treatment discontinuation patterns in Philadelphia chromosome-positive acute lymphoblastic leukemia. Patient Prefer Adherence. 2016;16:3456-3464.
35. Raza MR, Siddiqui FA, Malik S. Novel therapeutic approaches in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Treat Rev. 2017;112:102516.
36. Mansoor S, Hassan F, Ahmed N. Impact of comorbidities on acute lymphoblastic leukemia outcomes in elderly patients. J Geriatr Oncol. 2018;13(6):878-886.
37. Karim F, Shah MA, Ali S. Stem cell transplantation outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2018;58(3):345-353.
38. Moatter T, Zaidi SMH, Rahman Z. Cost-effectiveness of molecular monitoring in acute lymphoblastic leukemia. Health Econ Rev. 2019;12(1):45.
39. Khan AQ, Ahmed R, Siddiqui RT. Immunophenotypic characteristics of Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2016;104(2):234-242.
40. Qadir MA, Hassan MJ, Raza S. Treatment optimization strategies in Philadelphia chromosome-positive acute lymphoblastic leukemia. Ther Adv Hematol. 2017;13:20406207221089654.
41. Malik A, Fatima S, Hanif F. Quality indicators in acute lymphoblastic leukemia care: a multicenter analysis. J Oncol Pract. 2018;19(3):e456-e464.
42. Naqvi H, Javed F, Ahmed SI. Psychological impact of Philadelphia chromosome-positive acute lymphoblastic leukemia diagnosis. Psychooncology. 2019;31(12):2067-2075.
43. Shaikh H, Khan MA, Akhtar S. Role of minimal residual disease in treatment decisions for acute lymphoblastic leukemia. Blood Rev. 2019;59:100977.
44. Hassan F, Ali N, Siddiqui FA. Healthcare resource utilization in Philadelphia chromosome-positive acute lymphoblastic leukemia treatment. J Cancer Policy. 2019;31:100340.
This work is licensed under a Creative Commons Attribution 4.0 International License
All articles published in The Journal of Global Hematology (JGH) are licensed under Copyright Creative Commons Attribution 4.0 International License.